The U.S. Food and Drug Administration has approved Otezla (apremilast) for the treatment of psoriatic arthritis in adults.
Manufactured by Summit, N.J.-based Celgene Corp., Otezla demonstrated improvements in symptoms of psoriatic arthritis, such as tender and swollen joints and physical function, in clinical trials.
More Articles on FDA Approvals:
FDA Approves Xolair for Chronic Hives
FDA Approves Neuraceq for Brain Imaging
FDA Approves Implantable Device for Certain Type of Hearing Loss